Search Results

CGN Hezhi® Proton Therapy System Clinical Performance Successfully Passes Expert Review

On July 31, the expert review meeting for the clinical performance evaluation of the CGN Hezhi® Proton Therapy System was held at the CGN Proton Therapy Equipment Manufacturing Base. Clinical experts from Sun Yat-sen University Cancer Center, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences, Sichuan Cancer Hospital, National Cancer Center/Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Hospital, and Shandong First Medical University Affiliated Cancer Hospital attended the review meeting.▲Expert review of CGN Hezhi® Proton Therapy System clinical performanceAt the review meeting, the relevant person in charge of CGN Medical Technology Co., Ltd. (hereinafter referred to as the "Company") introduced that the comprehensive verification platform for the proton therapy system has achieved full-process independent controllability from design, procurement, production,...

2026-08-12

China's First Qualification for Radiation Health Testing and Evaluation of BNCT Equipment Approved

Recently, the Beijing Municipal Health Commission, in accordance with the "Administrative Measures for Radiation Health Technical Service Institutions" (Guoweiban ZhiJian Fa [2026] No. 1), organized experts to conduct on-site reviews of two qualification expansion applications submitted by the National Center for Occupational Safety and Health under the National Health Commission. The projects include performance testing and evaluation of Boron Neutron Capture Therapy (BNCT) equipment and thyroid iodine-131 testing. During the review process, the expert panel conducted a comprehensive examination of the center's management system, personnel allocation, instruments and equipment, and technical capabilities related to radiation health testing and evaluation through document review, technical inquiries, on-site practical operations, and simulated demonstrations...

2026-08-12

Australia's OPAL Multipurpose Reactor Marks 20 Years of Operation: Supporting Nuclear Medicine, Industrial Silicon Irradiation, and Neutron Science

The OPAL multipurpose reactor at the Lucas Heights campus of the Australian Nuclear Science and Technology Organisation (ANSTO), located south of Sydney, has marked the 20th anniversary of achieving first criticality. On August 12, 2006, OPAL achieved a self-sustaining controlled nuclear chain reaction, marking the facility's transition from the construction phase to the scientific operations phase. ANSTO stated that over the past 20 years, OPAL has become one of Australia's key nuclear science infrastructures, serving multiple fields including medicine, industry, and scientific research. OPAL is not a power reactor and is not used for electricity generation. According to available information, Australian federal law and relevant state and territory legislation prohibit the construction of nuclear power reactors, fuel fabrication, and waste disposal facilities. Unlike power reactors used for...

2026-08-12

Leshan Accelerates Construction of Medical Isotope Production Base to Promote Domestic Substitution of "Anti-Cancer Nuclear Drugs"

On August 11, at the Leshan special press conference of "Myriad Scenes in Sichuan · Embarking on the '15th Five-Year Plan'", Leshan Mayor Zhao Yingchun stated that Leshan is accelerating the construction of the largest and most comprehensive medical isotope production base in China. Upon completion, the project will help break the foreign monopoly and import dependence on related products, promote the domestic substitution of anti-cancer nuclear drugs, and enable more patients to access domestically produced drugs with lower prices and better efficacy. Zhao Yingchun noted that during the "14th Five-Year Plan" period, Leshan has focused on building the "China Green Silicon Valley", a world-class tourist destination, and a major regional transportation and logistics hub in the province, continuously promoting high-quality development, with its economic output surpassing 250 billion yuan...

2026-08-12

University of Tokyo and University of York Successfully Validate Positronium Ratio Imaging Principle for the First Time

A research team from the Graduate School of Engineering at the University of Tokyo and the University of York in the UK established a novel geometric imaging principle utilizing positron three-photon decay. Using a gamma-ray measurement system comprising scintillators and silicon photomultipliers (SiPMs), along with the existing PET radiopharmaceutical ^18F-FDG, they successfully visualized the positronium three-photon decay ratio for the first time, completing the proof-of-principle for Positronium Ratio Imaging (PRI). The findings were published in *Communications Physics*. Current clinical nuclear medicine PET examinations primarily utilize gamma rays generated from two-photon annihilation between positrons and electrons to visualize drug accumulation in the body. While this method provides quantitative information on metabolism or drug uptake, it offers limited insight into microenvironmental features such as tissue hypoxia, which are closely related to disease malignancy. In recent years, researchers have attempted to obtain additional tissue information through the average lifetime of positronium formed during positron annihilation, but this approach typically requires the introduction of special nuclides or agents, limiting its practical application.

2026-08-12

LG Electronics Launches FDA-Approved 40-Inch Diagnostic Monitor for B2B Medical Imaging Market

LG Electronics announced on August 12 that it has launched a new 40-inch diagnostic monitor, the 40HT513D, targeting the business-to-business (B2B) medical display market. The product has received approval from the U.S. Food and Drug Administration (FDA) and is primarily intended for medical image interpretation. According to the company, the 40HT513D features a curved IPS black panel with a 21:9 aspect ratio and a resolution of 5120×2160, delivering approximately 11 million pixels. LG Electronics stated that this design consolidates image reading tasks that previously required three 3-megapixel monitors into a single screen. Physicians can simultaneously view and compare current and historical images from X-ray, CT scans, and MRI scans on the same display...

2026-08-12

China Bio-Pharma: Enters Cooperation Agreement with Stella Pharma on Boron Neutron Therapy Drug

China Bio-Pharma Holdings Limited announced on August 12 that the company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., and Japan's Stella Pharma Corporation signed a legally binding Master Cooperation Agreement on August 11, 2026, to jointly advance the development and commercialization of Steboronine in China. Steboronine is described in the announcement as the world's first approved boron neutron therapy drug, applied in Boron Neutron Capture Therapy (BNCT). Under the agreement, the cooperation between the two parties is divided into a development phase and a commercialization phase. During the development phase, the cooperation aims to leverage real-world data, real-world evidence, and real-world studies generated by the China Bio-Pharma Group to facilitate Stella Pharma in obtaining and maintaining, as soon as possible, marketing approval from China's National Medical Products Administration (NMPA) for Steboronine for the treatment of head and neck cancer; after Stella Pharma obtains marketing and manufacturing approval from the Japanese government for Steboronine for meningioma, the relevant China filings may also be extended to the meningioma indication.

2026-08-12

University of Missouri Receives $1 Million Grant to Research New FLASH Radiotherapy System

On August 11, researchers at the University of Missouri School of Medicine received a $1 million grant from the National Institutes of Health to study a new technology in cancer radiotherapy—the TheryQ FLASHKNiFE system. The project is funded through June 2027. A long-standing challenge in cancer treatment is how to kill tumor cells while protecting surrounding healthy tissue as much as possible. Existing radiotherapy can already achieve millimeter-level precision, but radiation damage and related side effects still limit the dose patients can safely receive. Unlike conventional approaches, FLASH radiotherapy does not primarily alter the direction of radiation beams, but instead delivers irradiation in an extremely short time at an ultra-high dose rate...

2026-08-12

US Oak Ridge National Laboratory Restarts Tungsten-188/Rhenium-188 Generator Production to Support Targeted Cancer Therapy Research

The US Department of Energy's Oak Ridge National Laboratory (ORNL) recently restarted and upgraded its tungsten-188/rhenium-188 (W-188/Re-188) generator manufacturing operations to meet the demand for the rare medical isotope rhenium-188 in targeted cancer therapy research. The laboratory last manufactured such generators in 2011. Radiochemist Becca Hores demonstrated the assembly process of the W-188/Re-188 generator. Depending on radioactivity levels, these generators must be assembled in gloveboxes or hot cells. Image credit: Maggie Gregg/Oak Ridge National Laboratory, US Department of Energy. Rhenium-188 is produced by the radioactive decay of tungsten-188. ORNL irradiates tungsten-186 in the High Flux Isotope Reactor (HFIR) to produce tungsten-188...

2026-08-12

Dong Nai Province, Vietnam: Nuclear Medicine Applications Drive Modern Medical Development, Focusing on Early Cancer Diagnosis and Precision Treatment

In the development of modern medicine, atomic energy technology is moving from the laboratory to the clinical frontline, becoming an important pillar for early disease screening, precise diagnosis, and effective treatment. In recent years, Dong Nai Province has continuously applied nuclear medicine technology to medical examinations and treatments, particularly in areas such as cancer, stroke, traumatic brain injury, cardiovascular diseases, and bone and joint injuries. Through equipment such as X-ray, gamma rays, CT, and MRI, doctors can observe deep structures and lesions of the human body within a relatively short time, giving patients the opportunity for earlier detection and faster intervention. At Dong Nai General Hospital, approximately 500 patients undergo X-ray or related imaging examinations each day, with digital X-ray systems and multi-slice spiral C...

2026-08-12

First batch of experimental stations at Russia's Siberian Circular Photon Source expected to be operational by end of 2026

On August 11, Russian President Vladimir Putin stated at a meeting of the Council for Science and Education that the first research stations of the Siberian Circular Photon Source (SKIF) synchrotron are expected to be commissioned by the end of 2026. At the meeting, Putin noted that the Siberian Circular Photon Source is currently one of the world's most powerful particle accelerators, with some parameters being unique, capable of helping researchers conduct in-depth studies of the structure of matter at the atomic and molecular levels. He also stated that Russia needs to accelerate the development of future technologies, concentrate efforts on priority tasks, and make more efficient use of national strategic scientific resources, including research institutions, advanced digital computing resources, and unique biological resources. The Siberian Circular Photon...

2026-08-12

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

Argentine CNEA Expert Appointed Vice Chair of European Working Group on Nuclear Medicine Isotope Supply Security

The Argentine National Atomic Energy Commission (CNEA) recently announced that Daniel Sestao, an engineer and the institution's radioisotope production manager, has been appointed Vice Chair of the Supply Security Working Group of the European Association of Nuclear Medicine. CNEA, which operates under the Nuclear Affairs Secretariat of Argentina's Ministry of Economy, views this appointment as recognition of its technical capabilities in nuclear medicine and its role in international collaboration. The Supply Security Working Group is composed of international experts and focuses on the continuity and sustainability of the medical radioisotope supply chain, covering strategic isotopes such as molybdenum-99, technetium-99m, and lutetium-177. These radioisotopes are widely used in the diagnosis and treatment of tumors and complex diseases, forming a critical component of the nuclear medicine system...

2026-08-11

Fujita Health University in Japan Advances Research on Expanding BNCT Indications for Deep-Seated Cancers, to Conduct 18F-FBPA PET Exploratory Evaluation

On August 10, Stella Pharma Corporation of Japan announced that it is collaborating with Fujita Health University and other institutions to advance research and development aimed at expanding Boron Neutron Capture Therapy (BNCT) to deep-seated cancers. As part of this project, Stella Pharma will participate in an exploratory study on 18F-FBPA uptake capacity in deep-seated cancers conducted by Fujita Health University. The study will use 18F-FBPA PET to evaluate the tumor accumulation of boron drugs used in BNCT in deep-seated cancers, and based on the findings, explore the possibility of expanding BNCT indications in the future. The study plans to collect data from 50 cases, including pancreatic cancer, hepatocellular carcinoma, and biliary tract cancer, to accumulate foundational evidence needed for the development of BNCT for deep-seated cancers. BNC...

2026-08-11

Morehead State University Receives $50,000 Grant to Support Nuclear Medicine Technology Bachelor's Program

Morehead State University in the United States recently received a $50,000 grant to strengthen its Bachelor of Science in Nuclear Medicine Technology program, supporting the university's efforts to train medical imaging professionals for Kentucky's healthcare system. The funding was provided by the Kentucky Board of Medical Imaging and Radiation Therapy and administered by the Kentucky Council on Postsecondary Education. The project funds were awarded through a competitive bidding process, with a focus on supporting nuclear medicine technology education programs in Kentucky, aiming to increase the number of qualified professionals entering the state's healthcare industry. The newly established nuclear medicine technology undergraduate program under Morehead State University's Department of Imaging Sciences will prepare students in the field of medical imaging...

2026-08-11